

BCBS Buy and Bill Policy Shifts

What Allergy Practices Must Know

Major payors such as Blue Cross Blue Shield are restricting Buy and Bill for certain biologics and directing distribution through Specialty Pharmacy networks.

Approximately **30 to 40 percent of practices** report reimbursement model changes in the past year.

Why Buy and Bill Mattered

- In office biologic purchase and administration
- Reimbursement under the medical benefit
- Drug margins offset declining office visit payments

For many allergy practices, this was a key margin stabilizer.

Consolidation Pressure

Platforms like Allervie promote centralized contracts, negotiating leverage, and short term financial certainty.

But consolidation is not the only path forward.

Current Impact on Practices

- Lost in office biologic revenue
- Increased prior authorizations and paperwork
- Reduced cash flow predictability

More than **70 percent of practices** previously relied on Buy and Bill as a revenue stabilizer.

The Bigger Picture

Buy and Bill is changing, not disappearing. Policies vary, and strategic navigation can still protect reimbursement.

Smart Practice Priorities

Operational efficiency and strong payer oversight can offset margin pressure, with workflow optimization **driving 15 to 25 percent gains in visit efficiency.**

[Read the Full Insight](#)